Introduction
Jaundice is an important problem in the first week of life. It is a cause of concern for the physician and a source of anxiety for the parents. High bilirubin levels may be toxic to the developing central nervous system and may cause neurological impairment even in term newborns. Nearly 60% of term newborn becomes visibly jaundiced in the first week of life. 1 In most cases, it is benign and no intervention is required. Approximately 5-10 % of them have clinically significant hyperbilirubinemia mandating the use of phototherapy .
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Physiological jaundice
Jaundice attributable to physiological immaturity of neonates to handle increased bilirubin production. Visible jaundice usually appears between 24-72 hours of age. Total serum bilirubin (TSB) level usually rises in full-term infants to a peak of 6 to 8 mg/dL by 3 days of age and then falls. A rise to 12mg/dL is in the physiologic range. In premature infants, the peak may be 10 to 12 mg/dL on the fifth day of life, possibly rising over 15 mg/dL without any specific abnormality of bilirubin metabolism. Levels under 2mg/dL may not be seen until one month of age in both full term and premature infants. 4 Safe bilirubin levels in preterms vary according to gestational age. 5 
Pathological jaundice
TSB concentrations have been defined as non-physiologic if concentration exceeds 5 mg/dl on first day of life in term neonate, 10 mg/dL on second day, or 12-13 thereafter. 6 Any TSB elevation exceeding 17 mg/dL should be presumed pathologic and warrants investigation for a cause and possible intervention, such as phototherapy. 7 Appearance of jaundice within 24 hours, peak TSB levels above the expected normal range (Fig. 1) jaundice beyond 3 weeks and conjugated bilirubin (dark urine staining the clothes and light colored stool) would be categorized under pathological jaundice.
Breast-feeding and jaundice
Exclusively breast-fed infants have a different pattern of physiological jaundice as compared to artificially fed babies. 7, 9, 10 Jaundice in breast-fed babies usually appears between 24-72 hours of age, peaks by 5-15 days of life and disappears by the third week of life. They have also been reported to have higher bilirubin levels. Schneider's metaanalysis of 25 studies has shown that 13% of breast-fed babies had peak TSB levels of 12 mg/dL or higher as compared to 4% of artificially fed babies. Authors have stated that this increased frequency is not related to characteristics of breast milk but rather to the pattern of breast-feeding. Decreased frequency of breast-feeding is associated with exaggeration of physiological jaundice. Encouraging a mother to breastfeed her baby at least 10-12 times per day would be helpful in the management of jaundice in a term healthy baby.
Breast milk jaundice
Approximately 2-4% of exclusively breast-fed term babies have jaundice in excess of 10 mg/dL in the third week of life. 12, 13 These babies with TSB beyond 10 mg/dL after the third week of life should be investigated for prolonged jaundice. A diagnosis of breast milk jaundice should be considered if the TSB is predominantly unconjugated, other causes of prolonged jaundice have been excluded and the infant is in good health. Mothers should be advised to continue breast-feeding frequently intervals and TSB levels usually decline over Downloaded from www.newbornwhocc.orga period of time. Interruption of breast-feeding is not recommended unless TSB level exceeds 20 mg/dl.
Clinical examination of jaundice
Originally described by Kramer 14 , dermal staining of bilirubin may be used as a clinical guide to the level of jaundice. Dermal staining in newborn progresses in a cephalo-caudal direction. The newborn should be examined in good daylight. The skin should be blanched with digital pressure and the underlying color of skin and subcutaneous tissue should be noted. A rough guide for level of dermal staining with level of bilirubin is included in Table   1 .
Newborns detected to have yellow discoloration of the skin beyond the legs should have an urgent laboratory confirmation for levels of TSB. Clinical assessment is not very reliable if a newborn has been receiving phototherapy and if the baby has dark skin. 
Is there evidence of hemolysis?
Setting of Rh or less frequently ABO incompatibility, onset of jaundice within 24 hours, presence of pallor and hydrops, presence of hepato-splenomegaly, presence of hemolysis on the peripheral blood smear, raised reticulocyte count (>8%), rapid rise of bilirubin (>5 mg/dl in 24 hours or >0.5 mg/dl/hr) or a suggestive family history of significant jaundice should raise a suspicion of hemolytic jaundice. However, end-tidal carbon monoxide corrected for ambient carbon monoxide (ETCO c ) levels can confirm the presence or absence of hemolysis, and measurement of ETCO c is the only clinical test that provides a direct measurement of the rate of heme catabolism and the rate of bilirubin production. 17 
Does the infant have an underlying serious disease? (sepsis, galactosemia)
Presence of lethargy, poor feeding, failure to thrive, hepato-splenomegaly, temperature instability or apnea may be a marker of an underlying serious disease.
Does the infant have cholestatic jaundice?
Presence of jaundice (>10 mg/dl) beyond 3 weeks, presence of dark urine (staining the clothes) or pale colored stools would suggest cholestatic jaundice.
Jaundice in a term healthy baby
Advise for physiological jaundice:
The parents should be explained about the benign nature of jaundice. The mother should be encouraged to breast-feed frequently. The newborn should be exclusively breast-fed with no top feeds, water or dextrose water. Mother should be told to bring the baby to the hospital if the baby looks too yellow or yellow discoloration of the skin beyond the legs . We usually do repeat TSB within 4 to 6 hrs if initial was TSB in or near the exchange transfusion range meanwhile blood is arranged for the exchange transfusion, so that exchange can be done if there is no significant fall in the TSB. In a healthy neonates without setting for hemolytic jaundice and TSB not near exchange range we repeat TSB after 12 to 24 hrs. In Rh isoimmunization we do repeat TSB at 8 to 12 hr interval for first 48 hrs and 12 to 24 hourly afterwards when probability of unexpected rise in TSB usually decreased.
We in neonatal division of AIIMS follows American Academy of Pediatrics (AAP)'s guidelines for initiating phototherapy in term and near term infants (fig 2) . 17 For preterm and VLBW infants guidelines for phototherapy are not so clear for lack of data. We follow the ranges given in table 3.
For paucity of evidence these phototherapy guidelines are given only for first week of life.
We follows the same guidelines for neonates with hyperbilirubinemia post first week of life, however these babies are probably less prone for bilirubin induced brain damage with similar TSB.
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Hemolytic jaundice
The common causes of hemolytic jaundice include Rh hemolytic disease, ABO incompatibility, G-6-PD deficiency and minor blood group incompatibility.
Rh hemolytic disease:
A baby born to an Rh-negative mother (and Rh-positive father) should have Rh typing and a Direct Coomb's test (DCT) on cord blood. Newborns suspected to have Rh isoimmunization should have a blood group and Rh typing, DCT, PCV and serum bilirubin on cord blood to facilitate early treatment. A reticulocyte count should be sent prior to the first exchange transfusion (ET). Intensive phototherapy (section 15.1) should be started at birth and continued till two consecutive readings are below phototherapy range. Indications for exchange transfusion at birth and subsequently at a later age are mentioned in Table 2 . 
ABO Incompatibility:
Babies born to women with O blood group should be closely monitored for jaundice and discharged after 72 hours. If the maternal blood is group O, Rh-positive, it is an option to test the cord blood for the infant's blood type and direct antibody test, but it is not required provided that there is appropriate surveillance, risk assessment before discharge, and follow-up. Jaundice due to ABO incompatibility usually appears in the first 24 hours. In the presence of significant jaundice or jaundice appearing within 24 hours, the work up for pathological jaundice as given in section 10.1 should be done. An approach to phototherapy and ET has been outlined in section 15.
Other hemolytic states:
G6PD deficiency, hereditary spherocytosis, minor group incompatibilities should be managed similar to ABO incompatibility. Investigations for G-6-PD deficiency should be considered in all term and near-term infants with jaundice requiring phototherapy, with a family history of significant jaundice or a geographic origin associated with G-6-PD deficiency.
Jaundice in preterm babies
In premature infants, the term 'physiologic jaundice' is of little value. In VLBW infants, TSB levels well within the "physiologic range" might be hazardous and sometimes need to be treated with phototherapy. 18 Clinicians should ensure that all premature infants are routinely monitored for the development of jaundice. Serum bilirubin should be measured at 24 hours of age with follow up estimations every 12-24 hours until the levels stabilize. Recommendations for starting phototherapy in VLBW infants have been mentioned in Table 3 . Bilirubin should Downloaded from www.newbornwhocc.orgbe repeated within 24-48 hours of stopping phototherapy or sooner if clinical jaundice reappears. Direct bilirubin should be measured weekly in infants on parentral nutrition.
As a rough guide in healthy low birth weight infants phototherapy should be started at a bilirubin level of 1% of the birth weight (in grams)e.g. a baby weighing 1000 grams should receive phototherapy if the bilirubin levels exceed 10 mg/dl. An exchange transfusion should be considered at a value of 5mg/dl higher than that for phototherapy (1% of birth weight + 5 mg/dl). A sick VLBW baby requires intervention at lower levels.
12.Small for gestational age (SGA) babies:
Bilirubin handling in newborn is related to maturity of liver, which is dependent upon gestational age. Gestational age and corresponding appropriate weight may be a better guide for intervention as compared to actual birth weight in SGA infants.
Jaundice in a sick newborn
At high bilirubin levels sick neonates are more prone for bilirubin induces brain damage than the healthy neonate of similar gestation and weight. Intervention for jaundice in this group should start at lower levels of TSB (at a centile line below the expected for that gestation in figure 2 & 3) .
Additional investigations in a sick newborn include direct bilirubin, septic screen, blood and urine culture and urine for reducing substances
Prolonged jaundice beyond 3 weeks:
This is defined as persistence of significant jaundice (10 mg/dl) beyond three weeks in a term baby. The common causes include breast milk jaundice, extravasated blood (cephalhematoma), ongoing hemolytic disease, G-6PD deficiency and hypothyroidism.
One should rule out cholestasis by noting the urine and stool color and checking the level of direct bilirubin. The diagnostic work up in such a newborn includes:
• Investigations to rule out cholestasis (stool color, urine color, direct and indirect bilirubin levels)
• Investigations to rule out ongoing hemolysis, G-6PD screen
• Investigations to rule out hypothyroidism
• Investigations to rule out urinary tract infection.
Treatment options:
Phototherapy Factors That Affect the Dose and Efficacy of phototherapy17
(a) Spectrum of light emitted: Blue-green spectrum is most effective. At these wavelengths, light penetrates skin well and is absorbed maximally by bilirubin. Use special blue tubes or LED light source with output in blue-green spectrum for intensive PT. (e) TSB level at start of PT The higher the TSB, the more rapid the decline in TSB with PT.
Use intensive PT for higher TSB levels. Anticipate a more rapid decrease in TSB when TSB >20 mg/dL (342 µmol/L).
Continuous phototherapy is better than intermittent phototherapy. Phototherapy should be interrupted in a newborn only during breast-feeding and nappy changes.
Conventional phototherapy:
If jaundice is non-hemolytic or rate of rise of jaundice is slow then one can use either conventional or fibre-optic phototherapy units. However, an exchange transfusion (ET) may be performed at the slightest suspicion of bilirubin encephalopathy irrespective of the bilirubin value.
When Should Phototherapy Be Stopped? : There is no standard for discontinuing phototherapy. For infants who are readmitted after their birth hospitalization (usually for TSB levels of 18 mg/dL or higher), phototherapy may be discontinued when the serum bilirubin level falls below 13 to 14 mg/dL. Discharge from the hospital need not be delayed to observe the infant for rebound. If phototherapy is used for infants with hemolytic diseases or is initiated early and discontinued before the infant is 3 to 4 days old, a followup bilirubin measurement within 24 hours after discharge is recommended. For infants who are readmitted with hyperbilirubinemia and then discharged, significant rebound is rare, but a repeat TSB measurement or clinical follow-up 24 hours after discharge is a clinical option.
Sunlight Exposure: Although sunlight provides sufficient irradiance in the 425-to 475-nm band to provide phototherapy, the practical difficulties involved in safely exposing a naked newborn to the sun either inside or outside (and avoiding sunburn) preclude the use of sunlight as a reliable therapeutic tool, and it therefore is not recommended. Other situations: Cross-matched with baby's blood group.
Exchange transfusion
Blood volume used:
• Partial exchange done at birth in Rh hemolytic disease with severe anemia / hydrops (aims at increasing the oxygen carrying capacity of blood): 50 ml/ kg of packed cells
• Double volume exchange: 2 x (80-100 ml/kg) x birth weight in Kg (arrange 70% PRBC and 30% FFP, so that PCV of whole arranged blood ~ 50-55)
Pharmacological treatment:
Phenobarbitone: It improves hepatic uptake, conjugation and excretion of bilirubin thus helps in lowering of bilirubin. However its effect takes time. When used prophylactically in a dose of 5 mg/kg for 3-5 days after birth, it has shown to effective in babies with hemolytic disease, extravasated blood and in preterms without any significant side effects.
Intravenous Immunoglobulins (IVIG):
High dose intravenous -globulin (IVIG) (0.5 to 1 gm/kg) has been shown to reduce the need for exchange transfusions in Rh and ABO hemolytic disease.
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Pharmacologic Therapy: There is now evidence that hyperbilirubinemia can be effectively prevented or treated with tin-mesoporphyrin, a drug that inhibits the production of heme oxygenase. Tin-mesoporphyrin is not approved by the US Food and Drug Administration. If approved, tin-mesoporphyrin could find immediate application in preventing the need for exchange transfusion in infants who are not responding to phototherapy.
Follow-up:
Babies with serum bilirubin ≥20 mg/dl and those who require exchange transfusion should be kept under follow-up in the high-risk clinic for neuro-developmental outcome. Hearing assessment (BERA) should be done at 0-3 months of corrected age. With prompt treatment, even very elevated serum bilirubin levels within the range of 25 to 29 mg/dl are not likely to result in long-term adverse effects on neurodevelopment. 19 Annexure: Table 2 . Indications for exchange transfusion in Rh Isoimmunization. 6 An exchange transfusion soon after birth is indicated if:
Cord bilirubin is ≥ 5mg/dl Cord Hb is ≤10 mg/dl, PCV <30 Previous sibling history and positive DCT. 
